{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:42:55Z","timestamp":1793050975716,"version":"4.5.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40265-025-02232-7","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T17:53:55Z","timestamp":1757008435000},"page":"1231-1251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy"],"prefix":"10.1007","volume":"85","author":[{"given":"Jennifer H.","family":"Cooperrider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2232_CR1","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1080\/10428194.2017.1386304","volume":"59","author":"U Yanamandra","year":"2018","unstructured":"Yanamandra U, Kumar SK. Minimal residual disease analysis in myeloma\u2014when, why and where. Leuk Lymphoma. 2018;59:1772\u201384.","journal-title":"Leuk Lymphoma"},{"key":"2232_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.12.009","author":"BA Derman","year":"2024","unstructured":"Derman BA, Fonseca R. Measurable residual disease and decision-making in multiple myeloma. Hematol Oncol Clin N Am. 2024. https:\/\/doi.org\/10.1016\/j.hoc.2023.12.009.","journal-title":"Hematol Oncol Clin N Am"},{"key":"2232_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","volume":"1","author":"M Roshal","year":"2017","unstructured":"Roshal M, Flores-Montero JA, Gao Q, Koeber M, Wardrope J, Durie BGM, et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv. 2017;1:728\u201332.","journal-title":"Blood Adv"},{"key":"2232_CR4","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc\u00eda-S\u00e1nchez O, B\u00f6ttcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094\u2013103.","journal-title":"Leukemia"},{"key":"2232_CR5","unstructured":"Adaptive Biotechnologies Corporation. clonoSEQ assay technical information. https:\/\/www.clonoseq.com\/sites\/default\/files\/clonoSEQ_TechnicalInformationSummary_21Sept2018.pdf. Accessed 10 Feb 2020."},{"key":"2232_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5858\/arpa.2020-0457-OA","volume":"146","author":"MO Hussaini","year":"2022","unstructured":"Hussaini MO, Srivastava J, Lee LW, Nishihori T, Shah BD, Alsina M, et al. Assessment of clonotypic rearrangements and minimal residual disease in lymphoid malignancies. Arch Pathol Lab Med. 2022;146:485\u201393.","journal-title":"Arch Pathol Lab Med"},{"key":"2232_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102016","volume":"60","author":"S Oliva","year":"2023","unstructured":"Oliva S, Genuardi E, Paris L, D\u2019Agostino M, Rogers J, Rota-Scalabrini D, et al. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing. EClinicalMedicine. 2023;60: 102016.","journal-title":"EClinicalMedicine"},{"key":"2232_CR8","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2911\u20138.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2232_CR9","doi-asserted-by":"publisher","unstructured":"Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D\u2019Agostino M et al. Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial. eClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102017.","DOI":"10.1016\/j.eclinm.2023.102017"},{"key":"2232_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3324\/haematol.2021.280051","volume":"108","author":"F Kraeber-Bod\u00e9r\u00e9","year":"2023","unstructured":"Kraeber-Bod\u00e9r\u00e9 F, Zweegman S, Perrot A, Hulin C, Caillot D, Facon T, et al. Prognostic value of positron emission tomography\/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study. Haematologica. 2023;108:621\u20136.","journal-title":"Haematologica"},{"key":"2232_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","volume":"13","author":"R Fonseca","year":"2023","unstructured":"Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, Gonz\u00e1lez V\u00e9lez M, Kosiorek HE, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023;13:1\u20139.","journal-title":"Blood Cancer J"},{"key":"2232_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdp329","volume":"21","author":"M Varettoni","year":"2010","unstructured":"Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21:325\u201330.","journal-title":"Ann Oncol"},{"key":"2232_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","volume":"97","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761\u20137.","journal-title":"Haematologica"},{"key":"2232_CR14","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1182\/blood-2022-170119","volume":"140","author":"S Richard","year":"2022","unstructured":"Richard S, Lancman G, Rossi A, Chari A, Parekh S, Sanchez L, et al. Extramedullary relapse post CAR-T. Blood. 2022;140:4301\u20132.","journal-title":"Blood"},{"key":"2232_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01068-w","volume":"14","author":"D Dima","year":"2024","unstructured":"Dima D, Abdallah A-O, Davis JA, Awada H, Goel U, Rashid A, et al. Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy. Blood Cancer J. 2024;14:1\u20139.","journal-title":"Blood Cancer J"},{"key":"2232_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30\u20134.","journal-title":"Blood"},{"key":"2232_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1345\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2232_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13244-023-01498-3","volume":"14","author":"S Keaveney","year":"2023","unstructured":"Keaveney S, Dragan A, Rata M, Blackledge M, Scurr E, Winfield JM, et al. Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study. Insights Imaging. 2023;14:170.","journal-title":"Insights Imaging"},{"key":"2232_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1148\/radiol.2019181949","volume":"291","author":"C Messiou","year":"2019","unstructured":"Messiou C, Hillengass J, Delorme S, Lecouvet FE, Moulopoulos LA, Collins DJ, et al. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS). Radiology. 2019;291:5\u201313.","journal-title":"Radiology"},{"key":"2232_CR20","first-page":"479","volume":"5","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, et al. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging. 2015;5:479\u201392.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2232_CR21","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2021.39.15_suppl.8012","volume":"39","author":"MF Kaiser","year":"2021","unstructured":"Kaiser MF, Porta N, Sharma B, Levine D, Koh D-M, Boyd K, et al. Prospective comparison of whole body MRI and FDG PET\/CT for detection of multiple myeloma and correlation with markers of disease burden: results of the iTIMM trial. J Clin Oncol. 2021;39:8012\u20138012.","journal-title":"J Clin Oncol"},{"key":"2232_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0153-9","volume":"8","author":"L Sanoja-Flores","year":"2018","unstructured":"Sanoja-Flores L, Flores-Montero J, Garc\u00e9s JJ, Paiva B, Puig N, Garc\u00eda-Mateo A, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8: 117.","journal-title":"Blood Cancer J"},{"key":"2232_CR23","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.21.01365","volume":"40","author":"J-J Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s J-J, Cedena M-T, Puig N, Burgos L, Perez JJ, Cordon L, et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:3151\u201361.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2232_CR24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia\u2013like multiple myeloma. J Clin Oncol. 2023;41:1383\u201392.","journal-title":"J Clin Oncol"},{"key":"2232_CR25","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Mor\u00e8 S, Corradini P, et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:3120\u201331.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2232_CR26","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1182\/blood.2019002610","volume":"134","author":"L Sanoja-Flores","year":"2019","unstructured":"Sanoja-Flores L, Flores-Montero J, Puig N, Contreras-Sanfeliciano T, Pontes R, Corral-Mateos A, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019;134:2218\u201322.","journal-title":"Blood"},{"key":"2232_CR27","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2022-167382","volume":"140","author":"L Notarfranchi","year":"2022","unstructured":"Notarfranchi L, Zherniakova A, Lasa M, Puig N, Cedena MT, Martinez-Lopez J, et al. Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow. Blood. 2022;140:2095\u20137.","journal-title":"Blood"},{"key":"2232_CR28","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.3324\/haematol.2017.169235","volume":"102","author":"A Oberle","year":"2017","unstructured":"Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, et al. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. Haematologica. 2017;102:e368\u201370.","journal-title":"Haematologica"},{"key":"2232_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","volume":"14","author":"R Vij","year":"2014","unstructured":"Vij R, Mazumder A, Klinger M, O\u2019Dea D, Paasch J, Martin T, et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2014;14:131-139.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2232_CR30","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","volume":"2","author":"C Mazzotti","year":"2018","unstructured":"Mazzotti C, Buisson L, Maheo S, Perrot A, Chretien M-L, Leleu X, et al. Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Adv. 2018;2:2811\u20133.","journal-title":"Blood Adv"},{"key":"2232_CR31","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1182\/blood-2023-182410","volume":"142","author":"BA Derman","year":"2023","unstructured":"Derman BA, Kubicki T, Simmons H, Afrough A, Zonder JA, Grinblatt DL, et al. Early peripheral blood minimal residual disease status by NGS in patients with newly diagnosed multiple myeloma (MM) on a phase 2 trial receiving elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd). Blood. 2023;142:1982.","journal-title":"Blood"},{"key":"2232_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1053\/j.seminhematol.2018.02.008","volume":"55","author":"KL Thoren","year":"2018","unstructured":"Thoren KL. Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease. Semin Hematol. 2018;55:41\u20133.","journal-title":"Semin Hematol"},{"key":"2232_CR33","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0581","author":"M Kohlhagen","year":"2020","unstructured":"Kohlhagen M, Dasari S, Willrich M, Hetrick M, Netzel B, Dispenzieri A, et al. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clin Chem Lab Med (CCLM). 2020. https:\/\/doi.org\/10.1515\/cclm-2020-0581.","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"2232_CR34","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","volume":"62","author":"JR Mills","year":"2016","unstructured":"Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, et al. Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. 2016;62:1334\u201344.","journal-title":"Clin Chem"},{"key":"2232_CR35","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1021\/pr400985k","volume":"13","author":"DR Barnidge","year":"2014","unstructured":"Barnidge DR, Dasari S, Botz CM, Murray DH, Snyder MR, Katzmann JA, et al. Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy. J Proteome Res. 2014;13:1419\u201327.","journal-title":"J Proteome Res"},{"key":"2232_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jmsacl.2024.02.002","volume":"32","author":"D Barnidge","year":"2024","unstructured":"Barnidge D, Troske D, North S, Wallis G, Perkins M, Harding S. Endogenous monoclonal immunoglobulins analyzed using the EXENT\u00ae solution and LC-MS. J Mass Spectrom Adv Clin Lab. 2024;32:31\u201340.","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"2232_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/clinchem\/hvz041","volume":"66","author":"M Zajec","year":"2020","unstructured":"Zajec M, Langerhorst P, VanDuijn MM, Gloerich J, Russcher H, van Gool AJ, et al. Mass spectrometry for identification, monitoring, and minimal residual disease detection of M-proteins. Clin Chem. 2020;66:421\u201333.","journal-title":"Clin Chem"},{"key":"2232_CR38","doi-asserted-by":"publisher","first-page":"12446","DOI":"10.1182\/blood-2022-160249","volume":"140","author":"K Li","year":"2022","unstructured":"Li K, Barnidge D, Krevvata M, Perkins MC, Verona R, Zudaire E. Comparison of the analytical performance of EXENT\u00ae, a mass spectrometry-based assessment of m-protein, to SPEP and NGS-based MRD in multiple myeloma patient samples. Blood. 2022;140:12446\u20137.","journal-title":"Blood"},{"key":"2232_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00408-4","volume":"11","author":"DL Murray","year":"2021","unstructured":"Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an international myeloma working group mass spectrometry committee report. Blood Cancer J. 2021;11:1\u20136.","journal-title":"Blood Cancer J"},{"key":"2232_CR40","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood.2024024041","volume":"144","author":"T Kubicki","year":"2024","unstructured":"Kubicki T, Dytfeld D, Barnidge D, Sakrikar D, Przyby\u0142owicz-Chalecka A, Jamroziak K, et al. Mass spectrometry\u2013based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024;144:955\u201363.","journal-title":"Blood"},{"key":"2232_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00624-6","volume":"12","author":"A Dispenzieri","year":"2022","unstructured":"Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, et al. Mass-fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT). Blood Cancer J. 2022;12:1\u20138.","journal-title":"Blood Cancer J"},{"key":"2232_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00772-9","volume":"13","author":"EK Mai","year":"2023","unstructured":"Mai EK, Huhn S, Miah K, Poos AM, Scheid C, Weisel KC, et al. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer J. 2023;13:1\u20139.","journal-title":"Blood Cancer J"},{"key":"2232_CR43","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41408-024-00995-y","volume":"14","author":"HV Giles","year":"2024","unstructured":"Giles HV, Drayson MT, Kishore B, Pawlyn C, Kaiser M, Cook G, et al. Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry. Blood Cancer J. 2024;14:50.","journal-title":"Blood Cancer J"},{"key":"2232_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01045-3","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, et al. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024;14:1\u20139.","journal-title":"Blood Cancer J"},{"key":"2232_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00418-2","volume":"11","author":"BA Derman","year":"2021","unstructured":"Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, et al. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021;11:1\u20134.","journal-title":"Blood Cancer J"},{"key":"2232_CR46","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1182\/blood-2021-151557","volume":"138","author":"N Puig","year":"2021","unstructured":"Puig N, Contreras Sanfeliciano T, Paiva B, Cedena MT, Rosinol L, Garcia-Sanz R, et al. Assessment of treatment response by IFE, next generation flow cytometry and mass spectrometry coupled with liquid chromatography in the GEM2012MENOS65 clinical trial. Blood. 2021;138:544.","journal-title":"Blood"},{"issue":"18","key":"2232_CR47","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1158\/1078-0432.CCR-21-0649","volume":"27","author":"M Liyasova","year":"2021","unstructured":"Liyasova M, McDonald Z, Taylor P, Gorospe K, Xu X, Yao C, et al. A personalized mass spectrometry-based assay to monitor M-protein in multiple myeloma patients (EasyM). Clin Cancer Res. 2021;27(18):5028\u201337.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2232_CR48","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1021\/acs.jproteome.0c01022","volume":"20","author":"Z McDonald","year":"2021","unstructured":"McDonald Z, Taylor P, Liyasova M, Liu Q, Ma B. Mass spectrometry provides a highly sensitive noninvasive means of sequencing and tracking M-protein in the blood of Multiple myeloma patients. J Proteome Res. 2021;20(8):4176\u201385. https:\/\/doi.org\/10.1021\/acs.jproteome.0c01022.","journal-title":"J Proteome Res"},{"key":"2232_CR49","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.1182\/blood-2022-155582","volume":"140","author":"MJ Slade","year":"2022","unstructured":"Slade MJ, Khalid A, Fiala MA, Liyasova M, Zaydman MA, McDonald Z, et al. Clonotypic mass spectrometry with Easym assay for detection of measurable residual disease in multiple myeloma. Blood. 2022;140:4376\u20137.","journal-title":"Blood"},{"key":"2232_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00803-z","volume":"13","author":"S Noori","year":"2023","unstructured":"Noori S, Wijnands C, Langerhorst P, Bonifay V, Stingl C, Touzeau C, et al. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J. 2023;13:1\u20133.","journal-title":"Blood Cancer J"},{"key":"2232_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00149","volume":"8","author":"F Kendrick","year":"2017","unstructured":"Kendrick F, Evans ND, Arnulf B, Avet-Loiseau H, Decaux O, Dejoie T, et al. Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma. Front Physiol. 2017;8: 149.","journal-title":"Front Physiol"},{"key":"2232_CR52","first-page":"106","volume":"48","author":"F Kendrick","year":"2015","unstructured":"Kendrick F, Harding S, Chappell MJ, Evans ND. Immunoglobulin G (IgG) and neonatal Fc-receptor (FcRn) dynamics in IgG multiple myeloma. IFAC-Pap. 2015;48:106\u201311.","journal-title":"IFAC-Pap"},{"key":"2232_CR53","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood.2021013794","volume":"139","author":"HV Giles","year":"2022","unstructured":"Giles HV, Cook MA, Drayson MT, Cook G, Wright NJ, North SJ, et al. Redefining nonmeasurable multiple myeloma using mass spectrometry. Blood. 2022;139:946\u201350.","journal-title":"Blood"},{"issue":"5","key":"2232_CR54","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1182\/blood.2024026028","volume":"145","author":"D Ikeda","year":"2024","unstructured":"Ikeda D, Aikawa S, Misono C, Oura M, Fujii F, Sakuma H, et al. Soluble B-cell maturation antigen levels for disease monitoring in oligosecretory and nonsecretory relapsed multiple myeloma. Blood. 2024;145(5):526\u201332.","journal-title":"Blood"},{"key":"2232_CR55","unstructured":"Adaptive Biotechnologies announces clinical lab fee schedule rate of $2,007 for clonoSEQ\u00ae test for minimal residual disease assessment is effective as of January 1st, 2025 | Adaptive Biotechnologies. https:\/\/investors.adaptivebiotech.com\/news-releases\/news-release-details\/adaptive-biotechnologies-announces-clinical-lab-fee-schedule. Accessed 22 May 2025."},{"key":"2232_CR56","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1111\/bjh.18948","volume":"202","author":"N Correia","year":"2023","unstructured":"Correia N, Dowling E, Popat R, Rabin N, Kyriakou C, Sive J, et al. Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma. Br J Haematol. 2023;202:e43\u20135.","journal-title":"Br J Haematol"},{"key":"2232_CR57","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.22.01916","volume":"41","author":"L Burgos","year":"2023","unstructured":"Burgos L, Tamariz-Amador L-E, Puig N, Cedena M-T, Guerrero C, Jel\u00ednek T, et al. Definition and clinical significance of the monoclonal gammopathy of undetermined significance\u2013like phenotype in patients with monoclonal gammopathies. J Clin Oncol. 2023;41:3019\u201331.","journal-title":"J Clin Oncol"},{"key":"2232_CR58","unstructured":"Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, et al. Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma. J Clin Oncol. 2024;0:JCO.24.00635."},{"key":"2232_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14:1\u20137.","journal-title":"Blood Cancer J"},{"key":"2232_CR60","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117:3025\u201331.","journal-title":"Blood"},{"key":"2232_CR61","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3324\/haematol.11534","volume":"92","author":"HJK van de Velde","year":"2007","unstructured":"van de Velde HJK, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica. 2007;92:1399\u2013406.","journal-title":"Haematologica"},{"key":"2232_CR62","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"2232_CR63","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien M-L, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364.","journal-title":"Blood"},{"key":"2232_CR64","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva B, San-Miguel J, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140:2423\u20138.","journal-title":"Blood"},{"key":"2232_CR65","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"2232_CR66","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"J-J Lahuerta","year":"2017","unstructured":"Lahuerta J-J, Paiva B, Vidriales M-B, Cord\u00f3n L, Cedena M-T, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2900\u201310.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2232_CR67","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1182\/blood-2023-189850","volume":"142","author":"T Kubicki","year":"2023","unstructured":"Kubicki T, Dytfeld D, Wrobel T, Jamroziak K, Robak P, Czyz J, et al. Longitudinal assessment of minimal residual disease (MRD) in the ATLAS randomized phase 3 trial of post-transplant treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide (R) alone in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2023;142:4715.","journal-title":"Blood"},{"key":"2232_CR68","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139:492.","journal-title":"Blood"},{"key":"2232_CR69","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1200\/JCO.20.01814","volume":"39","author":"H Avet-Loiseau","year":"2021","unstructured":"Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39:1139\u201349.","journal-title":"J Clin Oncol"},{"key":"2232_CR70","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/leu.2014.219","volume":"29","author":"S Ferrero","year":"2015","unstructured":"Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics\u2019 impact on survival. Leukemia. 2015;29:689\u201395.","journal-title":"Leukemia"},{"key":"2232_CR71","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, et al. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022;6:808\u201317.","journal-title":"Blood Adv"},{"key":"2232_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-025-01219-7","volume":"15","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Medvedova E, Dhakal B, Dholaria BR, Godby KN, Bal S, et al. Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy. Blood Cancer J. 2025;15:1\u20134.","journal-title":"Blood Cancer J"},{"key":"2232_CR73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2023022083","volume":"143","author":"C Guerrero","year":"2024","unstructured":"Guerrero C, Puig N, Cedena M-T, Calasanz M-J, Gutierrez NC, Fernandez M, et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024;143:597\u2013603.","journal-title":"Blood"},{"key":"2232_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00705-6","volume":"12","author":"BA Derman","year":"2022","unstructured":"Derman BA, Jakubowiak AJ, Thompson MA. Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022;12:1\u20134.","journal-title":"Blood Cancer J"},{"key":"2232_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10:1\u201311.","journal-title":"Blood Cancer J"},{"key":"2232_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021. https:\/\/doi.org\/10.1016\/S1470-2045(21)00466-6.","journal-title":"Lancet Oncol"},{"key":"2232_CR77","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J Clin Oncol. 2023;41:1590\u20139.","journal-title":"J Clin Oncol"},{"key":"2232_CR78","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol"},{"key":"2232_CR79","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132\u201347.","journal-title":"N Engl J Med"},{"key":"2232_CR80","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"2232_CR81","unstructured":"FDA. Clinical trial considerations to support accelerated approval of oncology therapeutics | FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics. Accessed 6 Nov 2024."},{"key":"2232_CR82","unstructured":"FDA. Research C for DE and hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. US Food Drug Adm. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and. Accessed 30 June 2023."},{"key":"2232_CR83","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144:359\u201367.","journal-title":"Blood"},{"key":"2232_CR84","unstructured":"Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, et al. Minimal residual disease\u2013based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials. J Clin Oncol. 2025;0:JCO-24-02020."},{"key":"2232_CR85","first-page":"49","volume":"1","author":"M Buyse","year":"2000","unstructured":"Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostat Oxf Engl. 2000;1:49\u201367.","journal-title":"Biostat Oxf Engl"},{"key":"2232_CR86","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz002","volume":"3","author":"W Xie","year":"2019","unstructured":"Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, et al. A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses. JNCI Cancer Spectr. 2019;3: pkz002.","journal-title":"JNCI Cancer Spectr"},{"key":"2232_CR87","unstructured":"FDA. April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement - 04\/12\/2024. FDA. 2024. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024. Accessed 6 Nov 2024."},{"key":"2232_CR88","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, Rosi\u00f1ol L, van der Klift M, Mina R, et al. Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. Blood. 2023;142:4.","journal-title":"Blood"},{"key":"2232_CR89","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"},{"key":"2232_CR90","unstructured":"Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 Trial. J Clin Oncol. 2024;0:JCO-24-02266."},{"key":"2232_CR91","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30:2235\u201341.","journal-title":"Nat Med"},{"key":"2232_CR92","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos M-A, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597\u2013609.","journal-title":"N Engl J Med"},{"key":"2232_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-024-03485-7.","journal-title":"Nat Med"},{"key":"2232_CR94","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ajh.26640","volume":"97","author":"S Bal","year":"2022","unstructured":"Bal S, Dhakal B, Silbermann RW, Schmidt TM, Dholaria B, Giri S, et al. Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. Am J Hematol. 2022;97:1170\u20137.","journal-title":"Am J Hematol"},{"key":"2232_CR95","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1182\/blood-2023-186834","volume":"142","author":"O Landgren","year":"2023","unstructured":"Landgren O, Maura F, Kazandjian D. Advance multicenter clinical trial: MRD-driven therapy in newly diagnosed multiple myeloma patients. Blood. 2023;142:3392.","journal-title":"Blood"},{"key":"2232_CR96","doi-asserted-by":"crossref","unstructured":"Landgren CO, Ye JC, Hillengass J, Sborov DW, Hoffman JE, Diamond B, et al. Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): the ADVANCE clinical trial. J Clin Oncol. 43(16):suppl.","DOI":"10.1200\/JCO.2025.43.16_suppl.7503"},{"key":"2232_CR97","doi-asserted-by":"crossref","unstructured":"Perrot A, Hulin C, Lambert J, Karlin L, Arnulf B, Rey P, et al. MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: primary endpoints of the phase 3 MIDAS trial. J Clin Oncol. 2025:43(suppl 16):abstr LBA7500.","DOI":"10.1200\/JCO.2025.43.16_suppl.7500"},{"key":"2232_CR98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200210","volume":"144","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Silbermann R, Schmidt TM, Medvedova E, Bal S, Giri S, et al. MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM)\u2014master-2 trial. Blood. 2024;144: 2000.1.","journal-title":"Blood"},{"key":"2232_CR99","doi-asserted-by":"crossref","unstructured":"Raab M. Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial. Paper presented at ASH Annual Meeting & Exposition, 8 December 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper206003.html. Accessed 17 Feb 2025.","DOI":"10.1182\/blood-2024-206003"},{"key":"2232_CR100","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013901.","journal-title":"Lancet Haematol"},{"issue":"12","key":"2232_CR101","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","volume":"21","author":"SK Kumar","year":"2023","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, et al. Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(12):1281\u2013301. https:\/\/doi.org\/10.6004\/jnccn.2023.0061.","journal-title":"J Natl Compr Canc Netw"},{"key":"2232_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757","volume":"46","author":"C Poh","year":"2021","unstructured":"Poh C, Keegan T, Rosenberg AS. Second primary malignancies in multiple myeloma: a review. Blood Rev. 2021;46: 100757.","journal-title":"Blood Rev"},{"key":"2232_CR103","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol L, Oriol A, R\u00edos R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142:1518\u201328.","journal-title":"Blood"},{"key":"2232_CR104","unstructured":"Malandrakis P. Sustained MRD negativity for three years can guide discontinuation of lenalidomide maintenance after ASCT in multiple myeloma: results from a prospective cohort study. Paper presented at ASH Annual Meeting & Exposition, 7 December 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper209826.html. Accessed 11 Jan 2025."},{"key":"2232_CR105","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1182\/blood.2024027686","volume":"145","author":"E Terpos","year":"2025","unstructured":"Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Kostopoulos IV, Eleutherakis-Papaiakovou E, Kanellias N, et al. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. Blood. 2025;145:2353\u201360.","journal-title":"Blood"},{"key":"2232_CR106","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/S2152-2650(24)01856-1","volume":"24","author":"N Korde","year":"2024","unstructured":"Korde N, Hassoun H, Landau H, Hamid S, Derkach A, Hultcrantz M, et al. OA-15 maintenance therapy cessation for multiple myeloma patients with three-year sustained MRD negative remissions. Clin Lymphoma Myeloma Leuk. 2024;24:S10\u20131.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2232_CR107","doi-asserted-by":"publisher","first-page":"7304","DOI":"10.1182\/blood-2022-170936","volume":"140","author":"K Sweiss","year":"2022","unstructured":"Sweiss K, Hofmeister CC, Zappia M, Frolov M, Benevolenskaya E, Quigley JG, et al. Free from maintenance drug therapy in multiple myeloma (the FREEDMM trial): a pilot study of minimal residual disease (MRD)-driven discontinuation of maintenance. Blood. 2022;140:7304\u20135.","journal-title":"Blood"},{"key":"2232_CR108","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/blood-2020-142913","volume":"136","author":"A Krishnan","year":"2020","unstructured":"Krishnan A, Hoering A, Hari P, Sexton R, Orlowski RZ. Phase III study of daratumumab\/rhuph20 (nsc- 810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapyin patients with multiple myeloma (mm) using minimal residual disease todirect therapy duration (DRAMMATIC study): SWOG s1803. Blood. 2020;136:21\u20132.","journal-title":"Blood"},{"key":"2232_CR109","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25:1003\u201314.","journal-title":"Lancet Oncol"},{"key":"2232_CR110","doi-asserted-by":"crossref","unstructured":"Zamagni E. Phase 3 study of teclistamab (Tec) in combination with lenalidomide (Len) and Tec alone versus len alone in newly diagnosed multiple myeloma (NDMM) as maintenance therapy following autologous stem cell transplantation (ASCT): safety run-in (SRI) results from the Majestec-4\/EMN30 Trial. Paper presented at ASH Annual Meeting & Exposition, 8 December 2024. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper205608.html. Accessed 13 Feb 2025.","DOI":"10.1182\/blood-2024-205608"},{"key":"2232_CR111","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8052","volume":"39","author":"S Kumar","year":"2021","unstructured":"Kumar S, Wei Z, Thompson MA, Snyder B, Weiss M, Wagner LI, et al. ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)\u2014a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation. J Clin Oncol. 2021;39: TPS8052\u2013TPS8052.","journal-title":"J Clin Oncol"},{"key":"2232_CR112","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood.2024025746","volume":"145","author":"A Badros","year":"2025","unstructured":"Badros A, Foster L, Anderson LD, Chaulagain CP, Pettijohn E, Cowan AJ, et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025;145:300\u201310.","journal-title":"Blood"},{"key":"2232_CR113","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1182\/blood-2023-189022","volume":"142","author":"FB Askeland","year":"2023","unstructured":"Askeland FB, Rasmussen A-M, Lysen A, Hauk\u00e5s E, Eilertsen AL, Moksnes M, et al. Will survival improve by treating multiple myeloma patients at MRD relapse? The remnant study. Blood. 2023;142:4755.","journal-title":"Blood"},{"key":"2232_CR114","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2232_CR115","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, et al. Cartitude-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023;41:8009\u20138009.","journal-title":"J Clin Oncol"},{"key":"2232_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-023-00820-y","volume":"13","author":"R Bansal","year":"2023","unstructured":"Bansal R, Baksh M, Larsen JT, Hathcock MA, Dingli D, Stewart AK, et al. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J. 2023;13:1\u20135.","journal-title":"Blood Cancer J"},{"key":"2232_CR117","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"2232_CR118","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, van de Donk NWCJ, Moreau P, Bhutani M, Oriol A, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:7540\u20137540.","journal-title":"J Clin Oncol"},{"key":"2232_CR119","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01.HS9.0000936220.68605.8b","volume":"7","author":"A Broijl","year":"2023","unstructured":"Broijl A, San-Miguel J, Suzuki K, Krishnan A, van de Donk N, Cook G, et al. P23 EMAGINE\/CARTITUDE-6: a randomized phase 3 study of dvrd followed by ciltacabtagene autoleucel versus DVRD followed by autologous stem cell transplant in transplant-eligible patients with newly diagnosed multiple myeloma. HemaSphere. 2023;7:22.","journal-title":"HemaSphere"},{"key":"2232_CR120","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1200\/JCO.2023.41.16_suppl.8003","volume":"41","author":"BR Dholaria","year":"2023","unstructured":"Dholaria BR, Weisel K, Mateos M-V, Goldschmidt H, Martin TG, Morillo D, et al. Talquetamab (Tal) + daratumumab (Dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results. J Clin Oncol. 2023;41:8003\u20138003.","journal-title":"J Clin Oncol"},{"key":"2232_CR121","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","volume":"24","author":"D Dytfeld","year":"2023","unstructured":"Dytfeld D, Wr\u00f3bel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:139\u201350.","journal-title":"Lancet Oncol"},{"key":"2232_CR122","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.pmn.2011.06.007","volume":"14","author":"B Tanasale","year":"2013","unstructured":"Tanasale B, Kits J, Kluin PM, Trip A, Kluin-Nelemans HC. Pain and anxiety during bone marrow biopsy. Pain Manag Nurs. 2013;14:310\u20137.","journal-title":"Pain Manag Nurs"},{"key":"2232_CR123","doi-asserted-by":"publisher","first-page":"e19529","DOI":"10.1200\/JCO.2019.37.15_suppl.e19529","volume":"37","author":"JJ Carlson","year":"2019","unstructured":"Carlson JJ, Eckert B, Zimmerman M. Cost-effectiveness of next-generation sequencing minimal residual disease testing during maintenance treatment for multiple myeloma. J Clin Oncol. 2019;37:e19529\u2013e19529.","journal-title":"J Clin Oncol"},{"key":"2232_CR124","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S2152-2650(24)01895-0","volume":"24","author":"A Perrot","year":"2024","unstructured":"Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, et al. OA-54 efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study. Clin Lymphoma Myeloma Leuk. 2024;24:S34\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2232_CR125","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","volume":"8","author":"BA Derman","year":"2022","unstructured":"Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD, et al. Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease-adapted study. JAMA Oncol. 2022;8:1278\u201386.","journal-title":"JAMA Oncol"},{"key":"2232_CR126","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2023-188844","volume":"142","author":"K Ramasamy","year":"2023","unstructured":"Ramasamy K, Cairns DA, Royle K-L, Cicero R, Olivier C, Barnard L, et al. Radar trial: MRD response adapted trial for newly diagnosed transplant eligible myeloma patients. Blood. 2023;142:3390.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02232-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02232-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02232-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:03:26Z","timestamp":1761077006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02232-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":126,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02232-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated figure file 2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.A.D. declares consultancy for Johnson & Johnson, Sanofi, Canopy, and Cota Inc.; the role of independent clinical trial reviewer for BMS; and research funding from GSK and Amgen. J.H.C. declares that her spouse is employed by Abbvie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No code was generated during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"J.H.C. and B.A.D. were responsible for reviewing the literature and writing and reviewing the body of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}